Shattuck Labs Inc
Company Profile
Business description
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Contact
500 W. 5th Street
Suite 1200
AustinTX78701
USAT: +1 512 900-4690
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
Reassuring organic growth for undervalued ASX share
stocks
Big IPOs are enticing but are they good investments?
stocks
This defensive ASX listed REIT offers a 5% yield
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,692.80 | 143.80 | -1.63% |
| CAC 40 | 7,972.39 | 108.35 | -1.34% |
| DAX 40 | 24,986.22 | 477.59 | -1.88% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,391.10 | 61.58 | -0.59% |
| HKSE | 22,410.80 | 430.82 | -1.89% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 56,436.65 | 3,007.56 | -5.06% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,592.60 | 137.80 | -1.58% |
| SSE Composite Index | 3,533.79 | 43.82 | -1.22% |